Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. / Rask, Lene; Balslev, Eva; Søkilde, Rolf; Høgdall, Estrid; Flyger, Henrik; Eriksen, Jens; Litman, Thomas.
In: Cellular oncology (Dordrecht), Vol. 37, No. 3, 06.2014, p. 215-227.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status
AU - Rask, Lene
AU - Balslev, Eva
AU - Søkilde, Rolf
AU - Høgdall, Estrid
AU - Flyger, Henrik
AU - Eriksen, Jens
AU - Litman, Thomas
PY - 2014/6
Y1 - 2014/6
N2 - PURPOSE: Therapeutic decisions in breast cancer are increasingly guided by prognostic and predictive biomarkers. Non-protein-coding microRNAs (miRNAs) have recently been found to be deregulated in breast cancers and, in addition, to be correlated with several clinico-pathological features. One of the most consistently up-regulated miRNAs is miR-21. Here, we specifically searched for differentially expressed miRNAs in high-risk breast cancer patients as compared to low-risk breast cancer patients. In the same patients, we also compared miR-21 expression with the expression of its presumed target PTEN.METHODS: Both microarray and RT-qPCR techniques were used to assess miRNA expression levels in lymph node-positive and -negative human invasive ductal carcinoma tissues. Simultaneously, PTEN protein expression levels were assessed using immunohistochemistry.RESULTS: miR-486-5p and miR-139-5p were found to be down-regulated in patients with lymph node metastases, whereas miR-21 was found to be up-regulated in patients with a positive lymph node status. miR-21 expression levels were found to significantly correlate with tumour size (r = 0.403, p = 0.009; Spearman's rank), whereas no relation was found between miR-21 and PTEN expression levels (Kruskal-Wallis test).CONCLUSION: Down-regulation of miR-486-5p and miR-139-5p, in conjunction with up-regulation of miR-21, may represent a useful signature for the identification of high-risk breast cancer patients.
AB - PURPOSE: Therapeutic decisions in breast cancer are increasingly guided by prognostic and predictive biomarkers. Non-protein-coding microRNAs (miRNAs) have recently been found to be deregulated in breast cancers and, in addition, to be correlated with several clinico-pathological features. One of the most consistently up-regulated miRNAs is miR-21. Here, we specifically searched for differentially expressed miRNAs in high-risk breast cancer patients as compared to low-risk breast cancer patients. In the same patients, we also compared miR-21 expression with the expression of its presumed target PTEN.METHODS: Both microarray and RT-qPCR techniques were used to assess miRNA expression levels in lymph node-positive and -negative human invasive ductal carcinoma tissues. Simultaneously, PTEN protein expression levels were assessed using immunohistochemistry.RESULTS: miR-486-5p and miR-139-5p were found to be down-regulated in patients with lymph node metastases, whereas miR-21 was found to be up-regulated in patients with a positive lymph node status. miR-21 expression levels were found to significantly correlate with tumour size (r = 0.403, p = 0.009; Spearman's rank), whereas no relation was found between miR-21 and PTEN expression levels (Kruskal-Wallis test).CONCLUSION: Down-regulation of miR-486-5p and miR-139-5p, in conjunction with up-regulation of miR-21, may represent a useful signature for the identification of high-risk breast cancer patients.
KW - Faculty of Health and Medical Sciences
U2 - 10.1007/s13402-014-0176-6
DO - 10.1007/s13402-014-0176-6
M3 - Journal article
C2 - 25027758
VL - 37
SP - 215
EP - 227
JO - Cellular oncology (Dordrecht)
JF - Cellular oncology (Dordrecht)
SN - 2211-3428
IS - 3
ER -
ID: 119643790